Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17006875 | TARGETED APHERESIS TO TREAT PREECLAMPSIA | January 2021 | July 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17257244 | Cannabidiol Combination Compositions | December 2020 | February 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17256406 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION AND OTHER MITOCHONDRIAL DISORDERS | December 2020 | July 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17254534 | Method of Inducing Dendritic and Synaptic Genesis in Neurodegenerative Chronic Diseases | December 2020 | May 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17253885 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND AMINO GROUP | December 2020 | May 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17122606 | Nucleic Acid Elution | December 2020 | April 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17119681 | NOVEL CROSSLINKED ALGINIC ACID | December 2020 | December 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 17251317 | FORMULATION COMPRISING ACTIVE PHARMACEUTICAL INGREDIENT | December 2020 | March 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17108623 | METHODS FOR TREATING DEMENTIA RELATED PSYCHOSIS | December 2020 | January 2023 | Abandon | 25 | 1 | 0 | No | No |
| 15734182 | Expanding the Chemical Substrates for Genetic Code Reprogramming | December 2020 | June 2023 | Allow | 30 | 2 | 1 | Yes | No |
| 17106617 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS ANIMAL FEED AND METHODS OF PRODUCING THEREOF | November 2020 | December 2022 | Allow | 25 | 1 | 0 | Yes | No |
| 17059163 | Rapidly Released Bioorthogonal Caging Groups | November 2020 | August 2023 | Abandon | 32 | 1 | 1 | No | No |
| 16951456 | METHOD AND KIT FOR CONCENTRATING TARGET DOUBLE-STRANDED NUCLEIC ACID MOLECULES USING A PYRROLE-IMIDAZOLE-CONTAINING POLYAMIDE | November 2020 | July 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16951994 | VITAMIN B12 COMPOUND SUPPLEMENTATION METHODS AND COMPOSITIONS | November 2020 | June 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 16950120 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | November 2020 | July 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 17098177 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | November 2020 | February 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17091404 | RETINOID TOPICAL COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS | November 2020 | August 2022 | Abandon | 22 | 1 | 0 | No | No |
| 17053317 | SIMPLE METHOD FOR THE PURIFICATION OF LACTO-N-NEOTETRAOSE (LNnT) FROM CARBOHYDRATES OBTAINED BY MICROBIAL FERMENTATION | November 2020 | February 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17084293 | GLUCAN FIBER COMPOSITIONS FOR USE IN LAUNDRY CARE AND FABRIC CARE | October 2020 | February 2022 | Allow | 15 | 0 | 0 | No | No |
| 17050818 | METHOD FOR ADJUSTING RAS UBIQUITINATION | October 2020 | June 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17048735 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF INFECTIONS AND ANTIBACTERIAL-INDUCED DYSFUNCTIONS | October 2020 | November 2023 | Allow | 37 | 3 | 1 | No | No |
| 17047209 | COMBINATION THERAPY FOR TREATMENT OF HCV | October 2020 | April 2023 | Allow | 30 | 2 | 1 | Yes | No |
| 17065242 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | October 2020 | January 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17036588 | NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS | September 2020 | June 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 17036995 | METHOD FOR PRODUCING ALLULOSE CRYSTALS | September 2020 | August 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 17034905 | ADDITIVE COMPOSITION FOR RUMINANT FEEDS | September 2020 | October 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 17029516 | OXIDIZED DEXTRAN | September 2020 | August 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 17012591 | Compositions Containing Adenosine Triphosphate (ATP) and Methods of Use | September 2020 | January 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17011675 | PARASITICIDAL COMPOSITIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF | September 2020 | May 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 16976832 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | August 2020 | August 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 17005187 | Compositions for use in the treatment of diabetes | August 2020 | August 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 17003531 | DOPAMINERGIC MIMETICS | August 2020 | August 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16998007 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BACTERIAL INFECTIONS AND RELATED SYMPTOMS | August 2020 | July 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16996090 | BROMODOMAIN INHIBITORS | August 2020 | August 2022 | Abandon | 24 | 0 | 1 | No | No |
| 16988617 | COMPOSITIONS AND METHOD FOR DETECTING MYCOBACTERIUM RIYADHENSE | August 2020 | May 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 16984898 | COMBINATIONS OF ACARICIDES AND INSECT GROWTH REGULATORS FOR CONTROL OF FLEAS WITHOUT EMESIS IN ANIMALS | August 2020 | April 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16945067 | TOPICAL COMPOSITIONS | July 2020 | May 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16945598 | STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS | July 2020 | July 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 16943379 | COMBINATION THERAPY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | July 2020 | August 2022 | Abandon | 24 | 2 | 0 | No | No |
| 16965211 | METHOD AND APPARATUS FOR THE PURIFICATION OF EXTRA-CHROMOSOMAL NUCLEIC ACIDS SEQUENCES | July 2020 | June 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 16937995 | METHOD OF TREATING METASTATIC CANCER IN A SUBJECT WITH A PROTEIN INHIBITOR | July 2020 | July 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 16930454 | FORMULATION WITH CANNABINOIDS | July 2020 | July 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16928664 | TOPICAL ANALGESIC | July 2020 | June 2021 | Allow | 11 | 1 | 0 | Yes | No |
| 16961963 | NUTRACEUTICAL COMPOSITION FOR THE ACTIVATION OF SIRTUINS WITH ANTI-AGING/REVERSE-AGING EFFECT | July 2020 | July 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16927897 | KITS AND METHODS FOR ASSESSING A CONDITION OR A RISK OF DEVELOPING A CONDITION, AND RELATED METHODS OF TREATMENT | July 2020 | March 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 16927816 | METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS | July 2020 | May 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16961429 | POLYMERS WITH RIGID SPACING GROUPS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | July 2020 | April 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 16961246 | Method for Isolating and Purifying Nucleic Acids Using A Solid-Liquid Phase System | July 2020 | February 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 16961214 | TOPICAL CAPECITABINE FOR THE TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS | July 2020 | May 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 16923729 | METHODS FOR TREATING INFLAMMATORY DISEASES | July 2020 | March 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16955621 | MATERIALS AND METHODS FOR DIETARY CALCIUM SUPPLEMENTATION OF ANIMALS | June 2020 | July 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16954090 | ANIMAL FEED MATERIAL | June 2020 | August 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16771856 | A NEW INFLAMMATION ASSOCIATED, LOW CELL COUNT ENTEROTYPE | June 2020 | December 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16771480 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | June 2020 | July 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16760482 | SELF-SUPPORTING HYDROGEL AND METHOD FOR PRODUCING SAME | June 2020 | February 2023 | Abandon | 34 | 0 | 1 | No | No |
| 16769670 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | June 2020 | June 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16769953 | PROCESS FOR THE MANUFACTURE OF MALTOSYL-ISOMALTOOLIGOSACCHARIDES (MIMO) | June 2020 | October 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16888272 | Process for Producing Fluorinated Compounds Using Alcohol Solvent Having Unsaturated Hydrocarbon | May 2020 | February 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 16768359 | REPURPOSCINS: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS FOR ERADICATING CANCER STEM CELLS | May 2020 | July 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 16886093 | ANIMAL TREATMENTS | May 2020 | July 2021 | Allow | 13 | 1 | 0 | Yes | No |
| 16883115 | Accelerated Treatment of COVID-19 and SAR's Type Viruses | May 2020 | August 2021 | Allow | 15 | 1 | 1 | Yes | No |
| 16882339 | INJECTABLE ANTIBIOTIC FORMULATIONS AND USE THEREOF | May 2020 | April 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16881154 | METHOD FOR PREVENTING THE FORMATION OF CALCIFIED DEPOSITS AND FOR INACTIVATING XENOANTIGENS IN BIOLOGICAL MATRICES | May 2020 | November 2023 | Allow | 42 | 3 | 1 | Yes | No |
| 16765359 | PREPARATION METHOD FOR VARIOUS NOVEL FUCOSYL OLIGOSACCHARIDES AND USE THEREOF | May 2020 | July 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16765273 | METHODS AND MATERIALS FOR ASSESSING AND TREATING OBESITY | May 2020 | April 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16876533 | METHODS OF DETECTING TUMOR PROGRESSION VIA ANALYSIS OF CELL-FREE NUCLEIC ACIDS | May 2020 | April 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16764919 | SEAWEED COMPOSITION | May 2020 | April 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 15931256 | MODULATORS OF ALPHA-1 ANTITRYPSIN | May 2020 | July 2023 | Allow | 38 | 2 | 1 | Yes | No |
| 16870984 | HYDROPHOBIC HIGHLY BRANCHED CARBOHYDRATE POLYMERS | May 2020 | May 2022 | Abandon | 24 | 1 | 1 | No | No |
| 16870017 | METHODS OF TREATING KELOIDS | May 2020 | February 2023 | Allow | 33 | 3 | 1 | Yes | No |
| 16762209 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | May 2020 | October 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16869461 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | May 2020 | October 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16761465 | METHODS FOR ISOLATING DNA FROM A BLOOD SAMPLE | May 2020 | October 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16761174 | METHOD FOR INACTIVATING MOLD SPORES | May 2020 | July 2022 | Allow | 27 | 1 | 0 | Yes | No |
| 16865179 | KILLING SENESCENT CELLS AND TREATING SENESCENCE-ASSOCIATED CONDITIONS USING A SRC INHIBITOR AND A FLAVONOID | May 2020 | July 2022 | Allow | 27 | 3 | 0 | Yes | No |
| 16860837 | Composition and Method for Improving the Appearance of Skin | April 2020 | July 2021 | Allow | 14 | 1 | 0 | Yes | No |
| 16860442 | IRON-POLYSACCHARIDE COMPLEXES AND METHODS FOR THE PREPARATION THEREOF | April 2020 | June 2021 | Allow | 14 | 1 | 0 | Yes | No |
| 16759074 | INTESTINAL IMMUNE-ENHANCING AGENT, FOOD PRODUCT, AND MEDICAMENT | April 2020 | January 2022 | Abandon | 21 | 1 | 0 | Yes | No |
| 16758648 | SELENOPROTEIN P FOR PREDICTION OF A FIRST CARDIOVASCULAR EVENT | April 2020 | August 2023 | Allow | 40 | 1 | 1 | Yes | No |
| 16856688 | TREATMENT OF A LIONFISH STING AND FORMULATIONS FOR USE THEREOF | April 2020 | December 2021 | Allow | 19 | 1 | 1 | Yes | No |
| 16757320 | Improved Delivery Systems for Moieties Including CBD Enhanced Combinations, Formulations and Chimeras | April 2020 | October 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16849747 | HIV PROTEASE INHIBITORS | April 2020 | December 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16844142 | BACTERIAL DERIVED NANOCELLULOSE TEXTILE MATERIAL | April 2020 | April 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 16843132 | COMPOSITIONS AND METHODS FOR INCREASING ENERGY METABOLISM | April 2020 | August 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16651431 | Tissue-Adhesive Polymers | March 2020 | February 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16830974 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | March 2020 | September 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16648057 | CELL-BASED ASSAY FOR QUANTIFYING THE POTENCY AND EFFICACY OF CANNABINOIDS AND/OR TERPENOIDS, AND METHODS OF USE THEREOF | March 2020 | July 2023 | Allow | 40 | 2 | 1 | Yes | No |
| 16647591 | INHIBITION OF AUTISM SPECTRUM DISORDER USING RIBOSOMAL READ-THROUGH COMPOUNDS | March 2020 | August 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16819811 | METHODS FOR THE DIAGNOSIS OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | March 2020 | March 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16819974 | OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL | March 2020 | August 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16647476 | USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DYSREGULATION | March 2020 | May 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16646854 | COMPOSITION FOR RELIEVING HANGOVER OR COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING ALCOHOLIC LIVER DISEASE, COMPRISING B-GLUCAN AS ACTIVE INGREDIENT | March 2020 | August 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16646853 | TREATMENT REGIMEN FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 INHIBITOR ALVOCIDIB | March 2020 | March 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16646578 | ANTI-AGING AGENT AND ANTI-AGING METHOD | March 2020 | August 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16646509 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | March 2020 | February 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16645096 | PROCESSES FOR THE FORMULATION OF PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN | March 2020 | March 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16803337 | GENE EXPRESSION PROFILES ASSOCIATED WITH CHRONIC ALLOGRAFT NEPHROPATHY | February 2020 | March 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16803411 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | February 2020 | October 2020 | Allow | 8 | 1 | 1 | Yes | No |
| 16803284 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | February 2020 | February 2021 | Allow | 11 | 1 | 1 | Yes | No |
| 16642440 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | February 2020 | January 2023 | Allow | 35 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHIAO, YIH-HORNG.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SHIAO, YIH-HORNG works in Art Unit 1623 and has examined 402 patent applications in our dataset. With an allowance rate of 74.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.
Examiner SHIAO, YIH-HORNG's allowance rate of 74.4% places them in the 41% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SHIAO, YIH-HORNG receive 1.73 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SHIAO, YIH-HORNG is 26 months. This places the examiner in the 73% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +76.9% benefit to allowance rate for applications examined by SHIAO, YIH-HORNG. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 32.6% of applications are subsequently allowed. This success rate is in the 70% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 63.6% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 85.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 94.1% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 68.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 67.7% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.